CarT is an expensive treatment, and you are right the cash burn is the threat.
Burn this quarter should be down a bit as the GBM ttial has been paused for redesign. But that will hopefully only be temporary.
Potential pivot points with CD17 CarT and NK cells in the next 6 months.
Now if Hopper has used his own shares to leverage other companies, isnt that him still using his own money? How does using shares as collateral cause detriment to others? I do that, to whom should I be apologising? I dont think you have a very good understanding of this.
The good news is Hopper hasn't organised a share buy back with its CR money to help ex directors exit the company at a better price. That was your fella wasnt it? Clever fella to organise that and have shareholders happy about it.
CHM Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)